“(3) A question that has been the subject of considerable research is whether the effect of fat on cancer is site-specific. Neither human nor animal studies are consistent in the association of fat intake with specific cancer sites.

(4) Another question that has been raised is whether the association of total fat intake to cancer risk is independently associated with energy intakes, or whether the association of fat with cancer risk is the result of the higher energy (caloric) intake normally associated with high fat intake. FDA has concluded that evidence from both animal and human studies indicates that total fat intake alone, independent of energy intake, is associated with cancer risk.

(b) Significance of the relationship between fat intake and risk of cancer. (1) Cancer is ranked as a leading cause of death in the United States. The overall economic costs of cancer, including direct health care costs and losses due to morbidity and mortality, are very high.” – CFR – Code of Federal Regulations Title 21

FDA Approved Drugs for Obesity

Trade or Brand NameGeneric Name (nonproprietaryCompanyType of DrugMechanism of ActionApprovedNotes
Alli, XenicalOrlistatGSK, Rochelipase inhibitorInhibits fab absorption in the intestinesFDA – 2007Available OTC (Alli) & perscription (Xenical)
QsymiaPhentermine-TopiramateVIVUS, Incsympathomimetic amine + anticonvulsantCombination drug that suppresses appetite and has effects on metabolismFDA – 2012
ContraveNaltrexone-BupropionOrexigen Therapeutics, Inc.antidepressant + opioid antogonistCombination drug affects the CNS to reduce hungerFDA – 2014
SaxendaLiraglutideNovo Nordiskinjectable GLP-1 receptor agonistGLP-1 receptor agonistFDA – 2020
WegovySemaglutideNovo Nordiskinjectable GLP-1 receptor agonistGLP-1 receptor agonistFDA -2012
ZepboundTirzepatideEli Lillyinjectable GLP-1 and GIP receptors dual agonistdual GLP-1 and GIP receptors agonistFDA – 2023